This update covers the latest health sector developments, including Moderna's COVID-19 vaccine review, GSK's asthma drug FDA ...

Recent health news showcases key developments across various sectors. Jiangsu Hengrui and Mirxes have strong trading debuts, ...

CAMBRIDGE, MA / ACCESS Newswire / May 23, 2025 / Moderna, Inc. (NASDAQ:MRNA) today announced that it has submitted an ...

The revised version of the vaccine, marketed as Spikevax, follows FDA guidance recommending that this year’s shots target ...

About a year after investing in Vigil Neuroscience Inc., Sanofi is now acquiring the Watertown biotech and its treatment in ...

Infectious disease experts say mRNA vaccines have been studied for decades, they are safe and effective, and were instrumental in saving lives during the COVID pandemic.

The FDA will limit the vaccine’s availability later this year to older adults and those who may be at risk of severe illness.

The FDA may limit annual COVID-19 boosters to high-risk groups unless clinical trials prove benefits for healthy adults under ...

Some members of the Vaccines and Related Biologics Products Advisory Committee worried that a strain change would require new ...

Analysts have set 12-month price targets for Moderna, revealing an average target of $37.62, a high estimate of $70.00, and a ...

FDA now requires Pfizer and Moderna COVID-19 vaccines to carry expanded warning labels about risks of myocarditis and pericarditis ...